Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SCN5A | Q14524 | 4/20 | 0.59 |
| ▸ | CYP1A2 | P05177 | 3/20 | 0.51 |
| ▸ | TGFBR1 | P36897 | 3/20 | 0.40 |
| ▸ | DYRK1A | Q13627 | 2/20 | 0.38 |
| ▸ | MAOA | P21397 | 1/20 | 0.38 |
| ▸ | MAOB | P27338 | 1/20 | 0.38 |
| ▸ | GRIN2B | Q13224 | 3/20 | 0.35 |
| ▸ | KCNN3 | Q9UGI6 | 2/20 | 0.35 |
| ▸ | PIK3CD | O00329 | 1/20 | 0.35 |
| ▸ | RXRA | P19793 | 1/20 | 0.35 |
| ▸ | GRIN1 | Q05586 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20190634 | 0.83 | SCN5A (0.62) | SCN5ATGFBR1DYRK1AMAOAMAOB | |
| SCHEMBL20189738 | 0.83 | SCN5A (0.65) | SCN5ACYP1A2TGFBR1DYRK1AMAOA | |
| SCHEMBL20190843 | 0.80 | SCN5A (0.61) | SCN5ACYP1A2TGFBR1MAOAMAOB | |
| SCHEMBL20190458 | 0.80 | CYP1A2 (0.48) | SCN5ACYP1A2MAOAMAOB | |
| SCHEMBL20190623 | 0.75 | SCN5A (1.00) | SCN5ACYP1A2TGFBR1DYRK1AMAOA | |
| SCHEMBL20190641 | 0.73 | CYP1A2 (0.66) | CYP1A2DYRK1AGRIN2BRXRAGRIN1 | |
| SCHEMBL23572407 | 0.70 | SCN5A (0.64) | SCN5ACYP1A2 | |
| SCHEMBL22066447 | 0.70 | CYP1A2 (0.46) | SCN5ACYP1A2DYRK1AMAOAMAOB | |
| SCHEMBL21835686 | 0.69 | CYP1A2 (0.58) | CYP1A2DYRK1A | |
| SCHEMBL20203846 | 0.69 | CYP1A2 (0.66) | SCN5ACYP1A2DYRK1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210188839-A1 | COMPOUNDS AND THEIR METHODS OF USE | PRAXIS PRECISION MEDICINES, INC. | 2021-06-24 | — | — | US | disclosed |
| US-20210188839-A1 | COMPOUNDS AND THEIR METHODS OF USE | PRAXIS PRECISION MEDICINES, INC. | 2021-06-24 | — | — | US | disclosed |
| WO-2018098500-A1 | COMPOUNDS AND THEIR METHODS OF USE | PRAXIS PRECISION MEDICINES, INC. (US) | 2018-05-31 | — | — | WO | disclosed |
| WO-2018098500-A1 | COMPOUNDS AND THEIR METHODS OF USE | PRAXIS PRECISION MEDICINES, INC. (US) | 2018-05-31 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210188839-A1 | COMPOUNDS AND THEIR METHODS OF USE | SCN1A, SCN3A, SCN1B | SCN5A 8/4885CYP1A2 1988/4885TGFBR1 4479/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.